Mesoblast Corporate Update and Financial Results Webcast
Mesoblast Limited (Nasdaq: MESO) announced it will host a webcast on June 2, 2021, to present operational highlights and financial results for the period ending March 31, 2021. The company specializes in allogeneic cellular medicines for inflammatory diseases, with a robust portfolio of late-stage product candidates and a global intellectual property portfolio extending through 2040. Mesoblast has completed Phase 3 trials for its products targeting advanced chronic heart failure and chronic low back pain, with ongoing developments for inflammatory conditions in children and adults.
- Complete Phase 3 trials for rexlemestrocel-L targeting chronic heart failure and chronic low back pain.
- Established commercial partnerships in Europe and China for Phase 3 assets.
- Strong global intellectual property portfolio extending to at least 2040.
- None.
NEW YORK, June 02, 2021 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, will host a webcast today to discuss operational highlights and financial results for the period ending March 31, 2021.
The webcast will begin at 6.30pm EDT, Wednesday, June 2; 8.30am AEST, Thursday, June 3, 2021. It can be accessed via:
https://webcast.boardroom.media/mesoblast-limited/20210602/NaN60b6e20c3acee00019e165bd
The archived webcast will be available on the Investor page of the Company’s website: www.mesoblast.com
About Mesoblast
Mesoblast is a world leader in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions. The Company has leveraged its proprietary mesenchymal lineage cell therapy technology platform to establish a broad portfolio of late-stage product candidates which respond to severe inflammation by releasing anti-inflammatory factors that counter and modulate multiple effector arms of the immune system, resulting in significant reduction of the damaging inflammatory process.
Mesoblast has a strong and extensive global intellectual property portfolio with protection extending through to at least 2040 in all major markets. The Company’s proprietary manufacturing processes yield industrial-scale, cryopreserved, off-the-shelf, cellular medicines. These cell therapies, with defined pharmaceutical release criteria, are planned to be readily available to patients worldwide.
Mesoblast has completed Phase 3 trials of rexlemestrocel-L for advanced chronic heart failure and chronic low back pain. Remestemcel-L is being developed for inflammatory diseases in children and adults including steroid refractory acute graft versus host disease and moderate to severe acute respiratory distress syndrome. Two products have been commercialized in Japan and Europe by Mesoblast’s licensees, and the Company has established commercial partnerships in Europe and China for certain Phase 3 assets.
Mesoblast has locations in Australia, the United States and Singapore and is listed on the Australian Securities Exchange (MSB) and on the Nasdaq (MESO). For more information, please see www.mesoblast.com, LinkedIn: Mesoblast Limited and Twitter: @Mesoblast
Release authorized by the Chief Executive.
For more information, please contact:
| Corporate Communications / Investors | Media |
| Paul Hughes | Kristen Bothwell |
| T: +61 3 9639 6036 | T: +1 917 613 5434 |
| E: investors@mesoblast.com | E: kbothwell@rubenstein.com |
FAQ
What are the recent financial highlights for Mesoblast Limited (MESO)?
When is Mesoblast's webcast for operational highlights?
What products are in Mesoblast's pipeline?
Where can I access the archived webcast from Mesoblast?
